

# TRANSPLANT DIAGNOSTICS: TECHNOLOGIES AND GLOBAL MARKETS



HLC193A  
October 2016

Yojana Jeevane  
*Project Analyst*

ISBN: 1-62296-376-8



**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

## TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY AND OBJECTIVE	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	3
SOURCE OF INFORMATION AND METHODOLOGY	3
ANALYST'S CREDENTIALS	4
RELATED BCC RESEARCH REPORTS	4
BCC RESEARCH WEBSITE	4
DISCLAIMER	5
CHAPTER 2 EXECUTIVE SUMMARY	7
EXECUTIVE SUMMARY	7
<i>SUMMARY TABLE GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	8
<i>SUMMARY FIGURE GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY REGION, 2015-2021 (\$ MILLIONS)</i>	8
CHAPTER 3 GLOBAL TRANSPLANT DIAGNOSTICS MARKET OVERVIEW	11
GLOBAL TRANSPLANT DIAGNOSTICS MARKET OVERVIEW	11
<i>TABLE 1 TYPES OF ORGAN REJECTION POST-TRANSPLANT PROCEDURES</i>	12
HLA TYPING IN TRANSPLANT DIAGNOSTICS	12
<i>TABLE 2 MAJOR TYPES OF HUMAN LEUKOCYTE ANTIGEN</i>	12
<i>TABLE 3 LIST OF AUTOIMMUNE DISEASES LINKED WITH HLA TYPES</i>	13
<i>TABLE 4 LIST OF FEW HLA TESTS COMMERCIALY AVAILABLE WITH CLINICAL APPLICATIONS</i>	13
MARKET EVOLUTION AND INNOVATIONS	14
NEXT-GENERATION SEQUENCING	15
PREPARATION OF LIBRARY	16
GENERATION OF CLUSTER	16
SEQUENCING OF THE FRAGMENTS	16
ANALYSIS OF THE DATA	16
GOVERNMENT REGULATIONS, MEDICAL ASSOCIATIONS, FOOD AND DRUG ADMINISTRATION AND INTERNATIONAL REGULATORY AGENCIES	17
GOVERNMENT REGULATORY GUIDELINES FOR HLA TYPING	17
MEDICAL ASSOCIATIONS AND SOCIETIES FOR HLA TYPING	18
ROLE OF FDA IN TRANSPLANT DIAGNOSTICS	18
Laboratory-Developed Tests (LDTs)	18
Nucleic Acid-Based Tests	19
<i>TABLE 5 NUCLEIC ACID TESTS APPROVED BY FDA</i>	20
DEMOGRAPHICS, INCIDENCE AND PREVALENCE RATES AND OTHER PARAMETERS INFLUENCING MARKET GROWTH	21
NORTH AMERICA	22
<i>FIGURE 1 NUMBER OF KIDNEY TRANSPLANTS IN NORTH AMERICA BY COUNTRY, 2015</i>	22
<i>FIGURE 2 NUMBER OF LIVER TRANSPLANTS IN NORTH AMERICA BY COUNTRY, 2015</i>	22

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>FIGURE 3 NUMBER OF ORGAN DONATIONS IN NORTH AMERICA BY TYPE OF DONOR, 2015</i>	23
<i>FIGURE 4 NUMBER OF TRANSPLANTS BY TYPE OF ORGAN IN U.S., JANUARY 1988-JUNE 2016</i>	24
<i>FIGURE 5 TRANSPLANT PROCEDURES PERFORMED BY ORGAN TYPE IN U.S., JANUARY 1988-JUNE 2016 (%)</i>	25
<i>FIGURE 6 NUMBER OF TRANSPLANTS BY AGE OF RECIPIENT IN U.S., JANUARY 1988-JUNE 2016</i>	26
<i>FIGURE 7 NUMBER OF TRANSPLANTS BY TYPE OF DONOR IN U.S., 2011-2015</i>	26
U.S. TRANSPLANT PROCEDURES	27
<i>FIGURE 8 NUMBER OF ORGAN DONATIONS IN U.S. BY TYPE OF DONOR, 2015</i>	28
<i>FIGURE 9 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN U.S. BY TYPE OF ORGAN, 2015</i>	28
CANADA TRANSPLANT PROCEDURES	29
<i>FIGURE 10 NUMBER OF ORGAN DONATIONS IN CANADA BY TYPE OF DONOR, 2015</i>	29
<i>FIGURE 11 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN CANADA BY TYPE OF ORGAN, 2015</i>	31
MEXICO TRANSPLANT PROCEDURES	31
<i>FIGURE 12 NUMBER OF ORGAN DONATIONS IN MEXICO BY TYPE OF DONOR, 2015</i>	32
<i>FIGURE 13 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN MEXICO BY TYPE OF ORGAN, 2015</i>	32
EUROPE	33
<i>FIGURE 14 NUMBER OF KIDNEY TRANSPLANTS IN EUROPE BY COUNTRY, 2015</i>	34
<i>FIGURE 15 NUMBER OF LIVER TRANSPLANTS IN EUROPE BY COUNTRY, 2015</i>	34
<i>FIGURE 16 NUMBER OF ORGAN DONATIONS IN EUROPE BY TYPE OF DONOR, 2015</i>	35
<i>FIGURE 17 HYPERTENSIVE DISEASES IN EUROPE BY COUNTRY, 2015 (%)</i>	35
<i>FIGURE 18 NUMBER OF DEATHS CAUSED BY CIRCULATORY SYSTEM DISEASES IN EUROPE BY COUNTRY, 2012 (%)</i>	36
<i>FIGURE 19 NUMBER OF ORGAN DONATIONS BY TYPE OF DONOR IN EUROPE (FRANCE, GERMANY AND UNITED KINGDOM), JANUARY 1988-JUNE 2016</i>	37
<i>FIGURE 20 NUMBER OF TRANSPLANT PROCEDURES BY TYPE OF ORGAN IN EUROPE (FRANCE, GERMANY AND UNITED KINGDOM), JANUARY 1988-JUNE 2016</i>	38
ASIA-PACIFIC	39
<i>FIGURE 21 NUMBER OF KIDNEY TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY, 2015</i>	40
<i>FIGURE 22 NUMBER OF LIVER TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY, 2015</i>	40
<i>FIGURE 23 NUMBER OF LIVER TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY AND TYPE OF DONOR, 2015</i>	41
China's Transplant Procedures	42
<i>FIGURE 24 NUMBER OF ORGAN/TISSUE TRANSPLANT PROCEDURES BY TYPE OF DONOR IN HONG KONG, 2015</i>	42
Japan Transplant Procedures	43
<i>FIGURE 25 NUMBER OF ORGAN TRANSPLANTS FROM DECEASED DONORS BY TYPE OF ORGAN IN JAPAN, 2015</i>	43
Australia Transplant Procedures	44
<i>FIGURE 26 NUMBER OF ORGAN DONATIONS BY TYPE OF DONOR IN AUSTRALIA, 2015</i>	44
<i>FIGURE 27 NUMBER OF ORGAN TRANSPLANTS BY TYPE OF ORGAN IN AUSTRALIA, 2015</i>	45
<i>FIGURE 28 NUMBER OF TISSUE TRANSPLANT PROCEDURES BY TYPE OF TISSUE IN AUSTRALIA, 2015</i>	46

TOPIC	PAGE NO.
India Transplant Procedures	47
ROW	47
CLINICAL GUIDELINES AND REIMBURSEMENT SCENARIO	47
GUIDELINES FOR TRANSPLANT DIAGNOSTICS	47
REIMBURSEMENT SCENARIO FOR TRANSPLANT DIAGNOSTICS	50
TABLE 6 LIST OF CPT CODES FOR HLA TYPING WITH SEROLOGICAL TESTING	51
TABLE 7 MAXIMUM FEES FOR PATHOLOGY LABORATORY, ON AND AFTER JANUARY 1, 2015 (\$)	51
TECHNOLOGY TRENDS	52
NOVEL INNOVATIONS FOR FUTURE OF TRANSPLANT DIAGNOSTICS	52
Biomarkers	52
TABLE 8 LABORATORY-BASED PRE-TRANSPLANTATION BIOMARKERS	53
TABLE 9 LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (ACUTE ALLOGRAFT REJECTION)	53
TABLE 10 LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (CHRONIC ALLOGRAFT DAMAGE)	54
TABLE 11 LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (ALLOGRAFT ACCOMMODATION)	54
TABLE 12 FDA-APPROVED BIOMARKERS	54
Bioprinting	55
TABLE 13 MATERIALS USED FOR BIOPRINTING	56
Organoids	56
TABLE 14 APPLICATION OF ORGANOIDS BY TYPE	57
Organoids in Transplant Diagnostics	58
U.S. HIV ORGAN POLICY EQUITY (HOPE) ACT, 2013	58
FIGURE 29 HISTORY OF THE HOPE ACT, 2013	59
ELIGIBILITY CRITERIA FOR HIV-POSITIVE DONORS AND RECIPIENTS	59
Eligibility Criteria for HIV-Positive Living Donors	59
Eligibility Criteria for HIV-Positive Deceased Donors	60
Eligibility Criteria for HIV-Positive Recipients	60
Transplant Hospital Criteria	60
Independent Advocates for HIV-Positive Living Organ Donor and Recipient	62
Responsibilities of the Independent HIV-Positive Recipient Advocate	62
Responsibilities of the Independent HIV-Positive Donor Advocate	62
Bio Specimens	63
KEY STRATEGIES	63
FIGURE 30 MAJOR STRATEGIES ADOPTED BY PLAYERS IN THE TRANSPLANT DIAGNOSTICS MARKET	63
TABLE 15 STRATEGIC DEVELOPMENT IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016 (NO./%)	64
TABLE 16 FDA APPROVALS FOR TRANSPLANT DIAGNOSTICS PRODUCTS, 2013-2016	64
TABLE 17 CE APPROVALS FOR TRANSPLANT DIAGNOSTICS PRODUCTS, 2013-2016	65
TABLE 18 NEW PRODUCT LAUNCHES IN TRANSPLANT DIAGNOSTICS MARKET, 2013-2016	66
TABLE 19 COMPANIES ADOPTING M &A AS A DEVELOPMENTAL STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET	68
TABLE 20 MERGERS AND ACQUISITIONS IN THE TRANSPLANT DIAGNOSTICS MARKET, 2012-2016	69

TOPIC	PAGE NO.
TABLE 21 COMPANIES ADOPTING AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS AS A DEVELOPMENTAL STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016	70
TABLE 22 LIST OF COMPANIES THAT ADOPTED AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS AS KEY STRATEGY, 2012-2016	71
TABLE 23 COMPANIES ADOPTING EXPANSION AS A KEY STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2011-2016	73
TABLE 24 COMPANIES ADOPTING INVESTMENT AS A KEY STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2013-2016	74
MARKET DYNAMICS	74
DRIVERS	74
Increasing Geriatric Population	74
FIGURE 31 GLOBAL POPULATION AGED 60 AND OVER BY REGION, 2015 (NO.)	74
Rising Chronic Diseases	76
TABLE 25 CHRONIC DISEASES LISTED BY THE WHO, 2010-2013	76
Increased Research and Development	77
TABLE 26 PRODUCT LAUNCHES IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016	77
RESTRAINTS	79
Challenges in HLA Sequencing	79
Demand and Supply Gap	79
FIGURE 32 WAITING LIST FOR ORGANS IN U.S. BY TYPE OF ORGAN AS OF JULY 15, 2016 (NO.)	80
FIGURE 33 WAITING LIST FOR ORGANS IN U.S. BY AGE OF DONOR AS OF JULY 15, 2016 (NO.)	80
OPPORTUNITIES	81
Increasing Need for Organ Transplants	81
Shift from Traditional Serological Typing to Gene-based HLA Typing	82
CHAPTER 4 TRANSPLANT DIAGNOSTICS MARKET ANALYSIS BY TECHNOLOGIES	84
TABLE 27 GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY TECHNOLOGIES, THROUGH 2021 (\$ MILLIONS)	84
MOLECULAR ASSAY TECHNOLOGIES	84
TABLE 28 GLOBAL MARKET FOR MOLECULAR ASSAYS BY TYPE, THROUGH 2021 (\$ MILLIONS)	85
TABLE 29 GLOBAL MARKET FOR MOLECULAR ASSAY BY REGION, THROUGH 2021 (\$ MILLIONS)	85
PCR-BASED MOLECULAR ASSAY	86
TABLE 30 GLOBAL MARKET FOR PCR-BASED MOLECULAR ASSAYS BY REGION, THROUGH 2021 (\$ MILLIONS)	86
FIGURE 34 WORKFLOW FOR POLYMERASE CHAIN REACTION	87
PCR-Sequence Specific Primer (SSP)	87
PCR Sequence-Specific Oligonucleotide (SSO)	88
SEQUENCING-BASED MOLECULAR ASSAY	88
TABLE 31 GLOBAL MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS BY REGION, THROUGH 2021 (\$ MILLIONS)	89
Sanger Sequencing	89
Next-Generation Sequencing	90
TABLE 32 COMPARISON OF NGS PLATFORMS	90
NONMOLECULAR ASSAY TECHNOLOGIES	91

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 33 GLOBAL MARKET FOR NONMOLECULAR ASSAYS BY TYPE, THROUGH 2021 (\$ MILLIONS)</i>	91
<i>TABLE 34 GLOBAL MARKET FOR NONMOLECULAR ASSAYS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	91
SEROLOGICAL ASSAYS	92
<i>TABLE 35 GLOBAL MARKET FOR SEROLOGICAL ASSAYS BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	92
<i>TABLE 36 SEROLOGICAL TYPES AND THEIR SENSITIVITY FOR ANTIBODY DETECTION (MCG/ML)</i>	92
MIXED LYMPHOCYTE CULTURE ASSAYS	93
<i>TABLE 37 GLOBAL MARKET FOR MLC ASSAYS, BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	93
CHAPTER 5 BY COMPONENT	95
<i>TABLE 38 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY COMPONENT, THROUGH 2021 (\$ MILLIONS)</i>	95
<i>TABLE 39 GLOBAL TRANSPLANT DIAGNOSTICS COMPONENT MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	95
INSTRUMENTS	95
<i>TABLE 40 GLOBAL TRANSPLANT DIAGNOSTICS INSTRUMENTS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	96
SEQUENCING SYSTEMS	96
READER/ANALYZER INSTRUMENTS	97
AUTOMATED DISPENSERS	97
NGS INSTRUMENTS	97
<i>TABLE 41 LIST OF FEW COMMERCIALY AVAILABLE INSTRUMENTS FOR TRANSPLANT DIAGNOSTICS</i>	98
REAGENTS AND CONSUMABLES	98
<i>TABLE 42 GLOBAL TRANSPLANT DIAGNOSTICS REAGENTS AND CONSUMABLES MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	99
CYTOTOXIC CONTROLS	99
B27 MONOCLONAL ANTIBODIES	99
BULK MONOCLONAL ANTIBODIES	100
FLUOROBeads ISOLATION REAGENTS	100
STAINING/QUENCHING REAGENTS	100
ISOLATION REAGENTS	100
POOLED HUMAN SERUM (PHS)	101
RABBIT COMPLEMENT	101
STAIN-FIXATION REAGENTS	101
SEROLOGICAL TYPING REAGENTS FOR HLA TYPING	102
<i>TABLE 43 LIST OF COMMERCIALY AVAILABLE REAGENTS FOR TRANSPLANT DIAGNOSTICS</i>	102
SOFTWARE AND SERVICES	103
<i>TABLE 44 GLOBAL TRANSPLANT DIAGNOSTICS SOFTWARE AND SERVICES MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	104
<i>TABLE 45 LIST OF COMMERCIALY AVAILABLE SOFTWARE AND SERVICES FOR TRANSPLANT DIAGNOSTICS</i>	104
CHAPTER 6 TRANSPLANT DIAGNOSTICS MARKET ANALYSIS BY END USER	106

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 46 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY END USER, THROUGH 2021 (\$ MILLIONS)</i>	106
<i>TABLE 47 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	106
HOSPITALS AND TRANSPLANT CENTERS	107
<i>TABLE 48 GLOBAL TRANSPLANT DIAGNOSTICS HOSPITALS AND TRANSPLANT CENTERS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	107
<i>TABLE 49 HOSPITALS PROVIDING HLA TYPING AND TRANSPLANT SERVICES</i>	107
RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS	108
<i>TABLE 50 GLOBAL TRANSPLANT DIAGNOSTICS RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	108
COMMERCIAL SERVICE PROVIDERS	109
<i>TABLE 51 GLOBAL TRANSPLANT DIAGNOSTICS COMMERCIAL SERVICE PROVIDERS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	109
CHAPTER 7 TRANSPLANT DIAGNOSTICS MARKET ANALYSIS BY APPLICATIONS	111
<i>TABLE 52 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY APPLICATIONS, THROUGH 2021 (\$ MILLIONS)</i>	111
<i>TABLE 53 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	111
RESEARCH	111
<i>TABLE 54 GLOBAL TRANSPLANT DIAGNOSTICS RESEARCH MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	112
BLOOD AND MARROW TRANSPLANT PROGRAMS	112
HEART/LUNG TRANSPLANTATION	113
<i>TABLE 55 SURVIVAL RATES OF PATIENTS</i>	113
DIAGNOSTICS	114
<i>TABLE 56 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)</i>	114
CHAPTER 8 COMPETITIVE LANDSCAPE	116
COMPETITIVE LANDSCAPE	116
<i>TABLE 57 KEY COMPETITIVE STRATEGIES, 2012-2016 (NO./%)</i>	117
PRODUCT APPROVALS AND LAUNCHES	117
<i>TABLE 58 PRODUCT APPROVAL AND LAUNCH STRATEGY BY COMPANY, 2013-2016 (NO./%)</i>	118
<i>TABLE 59 LIST OF KEY PRODUCT APPROVALS AND LAUNCHES ANNOUNCED, 2013-2016</i>	118
MERGERS AND ACQUISITIONS	121
<i>TABLE 60 MERGER AND ACQUISITION STRATEGY BY COMPANIES, 2012-2016 (NO./%)</i>	122
<i>TABLE 61 LIST OF KEY MERGERS AND ACQUISITIONS ANNOUNCED, 2013-2016</i>	123
AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS	124
<i>TABLE 62 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS STRATEGY BY COMPANIES, 2012-2016 (NO./%)</i>	125
<i>TABLE 63 LIST OF KEY AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS ANNOUNCED, 2012-2016</i>	125
EXPANSION	127
<i>TABLE 64 EXPANSION STRATEGIES BY COMPANIES, 2011-2016 (NO./%)</i>	128
<i>TABLE 65 LIST OF KEY EXPANSIONS ANNOUNCED, 2011-2016</i>	128

<b>TOPIC</b>	<b>PAGE NO.</b>
INVESTMENTS	129
TABLE 66 INVESTMENTS STRATEGY BY COMPANIES, 2012-2016 (NO./%)	129
TABLE 67 LIST OF KEY INVESTMENTS ANNOUNCED, 2012-2016	130
CHAPTER 9 REGIONAL ANALYSIS	132
TABLE 68 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	132
NORTH AMERICA	132
TABLE 69 NORTH AMERICAN TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 (\$ MILLIONS)	133
TABLE 70 NORTH AMERICAN TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 (\$ MILLIONS)	133
TABLE 71 COMMERCIAL TRANSPLANT DIAGNOSTICS PRODUCTS APPROVED BY THE FDA	133
TABLE 72 MAJOR TRANSPLANT DIAGNOSTICS COMPANIES BASED IN THE UNITED STATES	134
EUROPE	134
TABLE 73 EUROPEAN TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 (\$ MILLIONS)	135
TABLE 74 EUROPEAN TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 (\$ MILLIONS)	135
SPAIN	135
TABLE 75 NUMBER OF ORGAN DONATIONS IN SPAIN BY TYPE OF DONOR, 2014	136
TABLE 76 NUMBER OF ORGAN TRANSPLANTS IN SPAIN BY TYPE OF ORGAN, 2014	136
ITALY	136
TABLE 77 NUMBER OF ORGAN TRANSPLANTS IN ITALY BY TYPE OF ORGAN, 2015	137
TABLE 78 NUMBER OF ORGAN DONATIONS IN ITALY BY TYPE OF DONOR, 2015	137
TURKEY	137
TABLE 79 NUMBER OF ORGAN DONATIONS IN TURKEY BY TYPE OF DONOR, 2015	138
TABLE 80 NUMBER OF ORGAN TRANSPLANTS IN TURKEY BY TYPE OF ORGAN, 2015	138
TABLE 81 CE APPROVAL FOR TRANSPLANT DIAGNOSTICS MARKET	138
TABLE 82 MAJOR EUROPEAN PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET	139
ASIA-PACIFIC	140
TABLE 83 ASIA-PACIFIC TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 (\$ MILLIONS)	140
TABLE 84 ASIA-PACIFIC TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 (\$ MILLIONS)	140
MALAYSIA	141
TABLE 85 NUMBER OF ORGAN DONATIONS IN MALAYSIA BY TYPE OF DONOR, 2013	141
TABLE 86 NUMBER OF ORGAN TRANSPLANTS IN MALAYSIA BY TYPE OF ORGAN, 2013	141
NEW ZEALAND	141
TABLE 87 NUMBER OF ORGAN DONATIONS IN NEW ZEALAND BY TYPE OF DONOR, 2015	142
TABLE 88 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN NEW ZEALAND BY TYPE OF ORGAN, 2015	142
TABLE 89 TRANSPLANT DIAGNOSTICS COMPANY PRESENT IN ASIA	142
REST OF THE WORLD	143
TABLE 90 ROW TRANSPLANT DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2021 (\$ MILLIONS)	143



<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 91 ROW TRANSPLANT DIAGNOSTICS MARKET BY END USER, THROUGH 2021 (\$ MILLIONS)</i>	143
BRAZIL	143
<i>TABLE 92 COMMUNICABLE AND NONCOMMUNICABLE DISEASES LEADING TO MORTALITY IN BRAZIL, 2014 (%)</i>	144
<i>TABLE 93 NUMBER OF ORGAN DONATIONS IN BRAZIL BY TYPE OF DONOR, 2015</i>	144
<i>TABLE 94 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN BRAZIL BY TYPE OF ORGAN, 2015</i>	144
ISRAEL	145
<i>TABLE 95 AGE ADJUSTED HOSPITALIZATION RATE DUE TO CHRONIC DISEASES IN ISRAEL, 2013 (PER 100,000 ABOVE 15 YEARS)</i>	145
<i>TABLE 96 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN ISRAEL BY TYPE OF ORGAN, 2015</i>	146
<i>TABLE 97 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN ISRAEL BY TYPE OF ORGAN, 2015</i>	146
IRAN	146
<i>TABLE 98 NUMBER OF ORGAN DONATIONS IN IRAN BY TYPE OF DONOR, 2015</i>	146
<i>TABLE 99 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN IRAN BY TYPE OF ORGAN, 2015</i>	147
<i>TABLE 100 NUMBER OF TISSUE TRANSPLANT PROCEDURES IN IRAN BY TYPE OF TISSUE, 2015</i>	147
SAUDI ARABIA	148
<i>TABLE 101 NUMBER OF ORGAN DONATIONS IN SAUDI ARABIA BY TYPE OF DONOR, 2015</i>	148
<i>TABLE 102 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN SAUDI ARABIA BY TYPE OF ORGAN, 2015</i>	148
CHAPTER 10 PATENT ANALYSIS	150
INTRODUCTION	150
<i>TABLE 103 PATENTS REGISTERED/APPROVED BY COUNTRY, 2010-2016 (NO./%)</i>	150
<i>FIGURE 35 PATENTS REGISTERED/APPROVED BY COUNTRY, 2010-2016 (%)</i>	150
UNITED STATES	151
<i>TABLE 104 PATENTS REGISTERED/APPROVED IN U.S. BY TYPE OF PRODUCT, 2010-2016 (NO./%)</i>	151
<i>FIGURE 36 PATENTS REGISTERED/APPROVED IN U.S. BY TYPE OF PRODUCT, 2010-2016 (%)</i>	152
CHINA	152
<i>TABLE 105 PATENTS REGISTERED/APPROVED IN CHINA BY TYPE OF PRODUCT, 2010-2016 (NO./%)</i>	153
<i>FIGURE 37 PATENTS REGISTERED/APPROVED IN CHINA BY TYPE OF PRODUCT, 2010-2016 (%)</i>	153
EUROPE	153
<i>TABLE 106 PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016 (NO./%)</i>	154
<i>TABLE 107 PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016</i>	154
<i>FIGURE 38 PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016 (%)</i>	155
<i>TABLE 108 PATENTS REGISTERED/APPROVED BY TYPE OF PRODUCT, 2010-2016 (NO./%)</i>	155
<i>FIGURE 39 PATENTS REGISTERED/APPROVED BY TYPE OF PRODUCT, 2010-2016 (%)</i>	156

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 109 PATENTS RELATED TO TRANSPLANTS</i>	157
CHAPTER 11 COMPANY PROFILES	167
ABBOTT LABORATORIES	167
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	167
RECENT DEVELOPMENTS	167
<i>TABLE 110 RECENT DEVELOPMENTS OF ABBOTT LABORATORIES</i>	167
ABBOTT LABORATORIES FINANCIALS	168
<i>TABLE 111 ABBOTT LABORATORIES FINANCIALS, 2013-2015 (\$ MILLIONS/%)</i>	168
AFFYMETRIX INC.	168
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	168
RECENT DEVELOPMENTS	169
<i>TABLE 112 RECENT DEVELOPMENTS OF AFFYMETRIX INC.</i>	169
AFFYMETRIX INC. FINANCIALS	169
<i>TABLE 113 AFFYMETRIX INC. FINANCIALS, 2012-2014 (\$ MILLIONS/%)</i>	169
ASTELLAS PHARMA INC.	169
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	170
ASTELLAS PHARMA INC. FINANCIALS	170
<i>TABLE 114 ASTELLAS PHARMA INC. FINANCIALS, 2013-2015 (\$ MILLIONS/%)</i>	170
BIOFORTUNA LTD.	170
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	171
RECENT DEVELOPMENTS	171
<i>TABLE 115 RECENT DEVELOPMENTS OF BIOFORTUNA LTD.</i>	171
BIOFORTUNA LTD. FINANCIALS	172
<i>TABLE 116 BIOFORTUNA LTD. FINANCIALS, 2013-2015 (\$ MILLIONS/%)</i>	172
BIO-RAD LABORATORIES	172
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	172
RECENT DEVELOPMENTS	173
<i>TABLE 117 RECENT DEVELOPMENTS OF BIO-RAD LABORATORIES</i>	173
BIO-RAD LABORATORIES FINANCIALS	173
<i>TABLE 118 BIO-RAD LABORATORIES FINANCIALS, 2013-2015 (\$ MILLIONS/%)</i>	173
CAREDX INC.	173
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	174
RECENT DEVELOPMENTS	174
<i>TABLE 119 RECENT DEVELOPMENTS OF CAREDX INC.</i>	174
CAREDX INC. FINANCIALS	175
<i>TABLE 120 CAREDX INC. FINANCIALS, 2012-2014 (\$ MILLIONS/%)</i>	175
DIASORIN S.P.A.	175
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	175
RECENT DEVELOPMENTS	176
<i>TABLE 121 RECENT DEVELOPMENTS OF DIASORIN S.P.A.</i>	176
FINANCIALS	176
<i>TABLE 122 DIASORIN S.P.A. FINANCIALS, 2013-2015 (\$ MILLIONS/%)</i>	176
F. HOFFMANN-LA ROCHE AG	177
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	177
RECENT DEVELOPMENTS	177
<i>TABLE 123 RECENT DEVELOPMENTS OF F. HOFFMANN-LA ROCHE AG</i>	177

TOPIC	PAGE NO.
F. HOFFMANN-LA ROCHE AG FINANCIALS	178
TABLE 124 F. HOFFMANN-LA ROCHE AG FINANCIALS, 2013-2015 (\$ MILLIONS/%)	178
FUJIREBIO EUROPE N.V.	178
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	179
GENDX (GENOME DIAGNOSTICS B.V.)	179
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	179
RECENT DEVELOPMENTS	180
TABLE 125 RECENT DEVELOPMENTS OF GENDX	180
ILLUMINA INC.	180
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	180
RECENT DEVELOPMENTS	181
TABLE 126 RECENT DEVELOPMENTS OF ILLUMINA INC.	181
ILLUMINA INC. FINANCIALS	182
TABLE 127 ILLUMINA INC. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	182
IMMUCOR INC.	182
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	182
RECENT DEVELOPMENTS	183
TABLE 128 RECENT DEVELOPMENTS OF IMMUCOR INC.	183
IMMUCOR INC. FINANCIALS	183
TABLE 129 IMMUCOR INC. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	183
LINKAGE BIOSCIENCES	184
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	184
RECENT DEVELOPMENTS	184
TABLE 130 RECENT DEVELOPMENTS OF LINKAGE BIOSCIENCES	184
LUMINEX CORP.	185
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	185
RECENT DEVELOPMENTS	185
TABLE 131 RECENT DEVELOPMENTS OF LUMINEX CORP.	185
LUMINEX CORP. FINANCIALS	186
TABLE 132 LUMINEX CORP. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	186
OLERUP SSP AB	186
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	186
RECENT DEVELOPMENTS	187
TABLE 133 RECENT DEVELOPMENTS OF OLERUP SSP AB	187
OMIXON BIOCOMPUTING LTD.	187
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	187
QIAGEN N.V.	188
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	188
RECENT DEVELOPMENTS	188
TABLE 134 RECENT DEVELOPMENTS OF QIAGEN N.V.	188
QIAGEN N.V. FINANCIALS	189
TABLE 135 QIAGEN N.V. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	189
SIGMA-ALDRICH CORP.	189
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	190
SIGMA-ALDRICH FINANCIALS	190
TABLE 136 SIGMA-ALDRICH FINANCIALS, 2013-2015 (\$ MILLIONS/%)	190
THERMO FISHER SCIENTIFIC INC.	190

<b>TOPIC</b>	<b>PAGE NO.</b>
TRANSPLANT DIAGNOSTICS PRODUCT PORTFOLIO	191
RECENT DEVELOPMENTS	191
<i>TABLE 137 RECENT DEVELOPMENTS OF THERMO FISHER SCIENTIFIC INC.</i>	191
THERMO FISHER SCIENTIFIC FINANCIALS	192
<i>TABLE 138 THERMO FISHER SCIENTIFIC FINANCIALS, 2013-2015 (\$ MILLIONS/%)</i>	192
TRANSPLANT GENOMICS INC.	192
RECENT DEVELOPMENTS	192
<i>TABLE 139 RECENT DEVELOPMENTS OF TRANSPLANT GENOMICS INC.</i>	193
CHAPTER 12 APPENDIX	195
<i>TABLE 140 LIST OF PATENTS ISSUED IN CANADA</i>	195
<i>TABLE 141 LIST OF PATENTS ISSUED IN CHINA</i>	195
<i>TABLE 142 LIST OF PATENTS IN ISSUED EUROPE (WO)</i>	196
<i>TABLE 143 LIST OF PATENTS ISSUED IN EUROPE</i>	197
<i>TABLE 144 LIST OF PATENTS ISSUED BY THE EUROPEAN PATENT OFFICE (EPO)</i>	197
<i>TABLE 145 LIST OF PATENTS ISSUED IN JAPAN</i>	197
<i>TABLE 146 LIST OF PATENTS ISSUED IN KOREA</i>	198
<i>TABLE 147 LIST OF PATENTS ISSUED IN THE RUSSIAN FEDERATION</i>	198
<i>TABLE 148 LIST OF PATENTS ISSUED IN SINGAPORE</i>	198

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY REGION, THROUGH 2021 (\$ MILLIONS)	8
TABLE 1 TYPES OF ORGAN REJECTION POST-TRANSPLANT PROCEDURES	12
TABLE 2 MAJOR TYPES OF HUMAN LEUKOCYTE ANTIGEN	12
TABLE 3 LIST OF AUTOIMMUNE DISEASES LINKED WITH HLA TYPES	13
TABLE 4 LIST OF FEW HLA TESTS COMMERCIALY AVAILABLE WITH CLINICAL APPLICATIONS	13
TABLE 5 NUCLEIC ACID TESTS APPROVED BY FDA	20
TABLE 6 LIST OF CPT CODES FOR HLA TYPING WITH SEROLOGICAL TESTING	51
TABLE 7 MAXIMUM FEES FOR PATHOLOGY LABORATORY, ON AND AFTER JANUARY 1, 2015 (\$)	51
TABLE 8 LABORATORY-BASED PRE-TRANSPLANTATION BIOMARKERS	53
TABLE 9 LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (ACUTE ALLOGRAFT REJECTION)	53
TABLE 10 LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (CHRONIC ALLOGRAFT DAMAGE)	54
TABLE 11 LABORATORY-BASED POST-TRANSPLANTATION BIOMARKERS (ALLOGRAFT ACCOMMODATION)	54
TABLE 12 FDA-APPROVED BIOMARKERS	54
TABLE 13 MATERIALS USED FOR BIOPRINTING	56
TABLE 14 APPLICATION OF ORGANOIDS BY TYPE	57
TABLE 15 STRATEGIC DEVELOPMENT IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016 (NO./%)	64
TABLE 16 FDA APPROVALS FOR TRANSPLANT DIAGNOSTICS PRODUCTS, 2013-2016	64
TABLE 17 CE APPROVALS FOR TRANSPLANT DIAGNOSTICS PRODUCTS, 2013-2016	65
TABLE 18 NEW PRODUCT LAUNCHES IN TRANSPLANT DIAGNOSTICS MARKET, 2013-2016	66
TABLE 19 COMPANIES ADOPTING M &A AS A DEVELOPMENTAL STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET	68
TABLE 20 MERGERS AND ACQUISITIONS IN THE TRANSPLANT DIAGNOSTICS MARKET, 2012-2016	69
TABLE 21 COMPANIES ADOPTING AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS AS A DEVELOPMENTAL STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016	70
TABLE 22 LIST OF COMPANIES THAT ADOPTED AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS AS KEY STRATEGY, 2012-2016	71
TABLE 23 COMPANIES ADOPTING EXPANSION AS A KEY STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2011-2016	73
TABLE 24 COMPANIES ADOPTING INVESTMENT AS A KEY STRATEGY IN TRANSPLANT DIAGNOSTICS MARKET, 2013-2016	74
TABLE 25 CHRONIC DISEASES LISTED BY THE WHO, 2010-2013	76
TABLE 26 PRODUCT LAUNCHES IN TRANSPLANT DIAGNOSTICS MARKET, 2012-2016	77
TABLE 27 GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY TECHNOLOGIES, THROUGH 2021 (\$ MILLIONS)	84
TABLE 28 GLOBAL MARKET FOR MOLECULAR ASSAYS BY TYPE, THROUGH 2021 (\$ MILLIONS)	85
TABLE 29 GLOBAL MARKET FOR MOLECULAR ASSAY BY REGION, THROUGH 2021 (\$ MILLIONS)	85
TABLE 30 GLOBAL MARKET FOR PCR-BASED MOLECULAR ASSAYS BY REGION, THROUGH 2021 (\$ MILLIONS)	86

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 31 GLOBAL MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS BY REGION, THROUGH 2021 (\$ MILLIONS)	89
TABLE 32 COMPARISON OF NGS PLATFORMS	90
TABLE 33 GLOBAL MARKET FOR NONMOLECULAR ASSAYS BY TYPE, THROUGH 2021 (\$ MILLIONS)	91
TABLE 34 GLOBAL MARKET FOR NONMOLECULAR ASSAYS BY REGION, THROUGH 2021 (\$ MILLIONS)	91
TABLE 35 GLOBAL MARKET FOR SEROLOGICAL ASSAYS BY REGION, THROUGH 2021 (\$ MILLIONS)	92
TABLE 36 SEROLOGICAL TYPES AND THEIR SENSITIVITY FOR ANTIBODY DETECTION (MCG/ML)	92
TABLE 37 GLOBAL MARKET FOR MLC ASSAYS, BY REGION, THROUGH 2021 (\$ MILLIONS)	93
TABLE 38 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY COMPONENT, THROUGH 2021 (\$ MILLIONS)	95
TABLE 39 GLOBAL TRANSPLANT DIAGNOSTICS COMPONENT MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	95
TABLE 40 GLOBAL TRANSPLANT DIAGNOSTICS INSTRUMENTS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	96
TABLE 41 LIST OF FEW COMMERCIALY AVAILABLE INSTRUMENTS FOR TRANSPLANT DIAGNOSTICS	98
TABLE 42 GLOBAL TRANSPLANT DIAGNOSTICS REAGENTS AND CONSUMABLES MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	99
TABLE 43 LIST OF COMMERCIALY AVAILABLE REAGENTS FOR TRANSPLANT DIAGNOSTICS	102
TABLE 44 GLOBAL TRANSPLANT DIAGNOSTICS SOFTWARE AND SERVICES MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	104
TABLE 45 LIST OF COMMERCIALY AVAILABLE SOFTWARE AND SERVICES FOR TRANSPLANT DIAGNOSTICS	104
TABLE 46 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY END USER, THROUGH 2021 (\$ MILLIONS)	106
TABLE 47 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	106
TABLE 48 GLOBAL TRANSPLANT DIAGNOSTICS HOSPITALS AND TRANSPLANT CENTERS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	107
TABLE 49 HOSPITALS PROVIDING HLA TYPING AND TRANSPLANT SERVICES	107
TABLE 50 GLOBAL TRANSPLANT DIAGNOSTICS RESEARCH LABORATORIES AND ACADEMIC INSTITUTIONS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	108
TABLE 51 GLOBAL TRANSPLANT DIAGNOSTICS COMMERCIAL SERVICE PROVIDERS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	109
TABLE 52 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY APPLICATIONS, THROUGH 2021 (\$ MILLIONS)	111
TABLE 53 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	111
TABLE 54 GLOBAL TRANSPLANT DIAGNOSTICS RESEARCH MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	112
TABLE 55 SURVIVAL RATES OF PATIENTS	113
TABLE 56 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	114
TABLE 57 KEY COMPETITIVE STRATEGIES, 2012-2016 (NO./%)	117
TABLE 58 PRODUCT APPROVAL AND LAUNCH STRATEGY BY COMPANY, 2013-2016 (NO./%)	118

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 59 LIST OF KEY PRODUCT APPROVALS AND LAUNCHES ANNOUNCED, 2013-2016	118
TABLE 60 MERGER AND ACQUISITION STRATEGY BY COMPANIES, 2012-2016 (NO./%)	122
TABLE 61 LIST OF KEY MERGERS AND ACQUISITIONS ANNOUNCED, 2013-2016	123
TABLE 62 AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS STRATEGY BY COMPANIES, 2012-2016 (NO./%)	125
TABLE 63 LIST OF KEY AGREEMENTS, COLLABORATIONS AND PARTNERSHIPS ANNOUNCED, 2012-2016	125
TABLE 64 EXPANSION STRATEGIES BY COMPANIES, 2011-2016 (NO./%)	128
TABLE 65 LIST OF KEY EXPANSIONS ANNOUNCED, 2011-2016	128
TABLE 66 INVESTMENTS STRATEGY BY COMPANIES, 2012-2016 (NO./%)	129
TABLE 67 LIST OF KEY INVESTMENTS ANNOUNCED, 2012-2016	130
TABLE 68 GLOBAL TRANSPLANT DIAGNOSTICS MARKET BY REGION, THROUGH 2021 (\$ MILLIONS)	132
TABLE 69 NORTH AMERICAN TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 (\$ MILLIONS)	133
TABLE 70 NORTH AMERICAN TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 (\$ MILLIONS)	133
TABLE 71 COMMERCIAL TRANSPLANT DIAGNOSTICS PRODUCTS APPROVED BY THE FDA	133
TABLE 72 MAJOR TRANSPLANT DIAGNOSTICS COMPANIES BASED IN THE UNITED STATES	134
TABLE 73 EUROPEAN TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 (\$ MILLIONS)	135
TABLE 74 EUROPEAN TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 (\$ MILLIONS)	135
TABLE 75 NUMBER OF ORGAN DONATIONS IN SPAIN BY TYPE OF DONOR, 2014	136
TABLE 76 NUMBER OF ORGAN TRANSPLANTS IN SPAIN BY TYPE OF ORGAN, 2014	136
TABLE 77 NUMBER OF ORGAN TRANSPLANTS IN ITALY BY TYPE OF ORGAN, 2015	137
TABLE 78 NUMBER OF ORGAN DONATIONS IN ITALY BY TYPE OF DONOR, 2015	137
TABLE 79 NUMBER OF ORGAN DONATIONS IN TURKEY BY TYPE OF DONOR, 2015	138
TABLE 80 NUMBER OF ORGAN TRANSPLANTS IN TURKEY BY TYPE OF ORGAN, 2015	138
TABLE 81 CE APPROVAL FOR TRANSPLANT DIAGNOSTICS MARKET	138
TABLE 82 MAJOR EUROPEAN PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET	139
TABLE 83 ASIA-PACIFIC TRANSPLANT DIAGNOSTIC MARKET BY COUNTRY, THROUGH 2021 (\$ MILLIONS)	140
TABLE 84 ASIA-PACIFIC TRANSPLANT DIAGNOSTIC MARKET BY END USER, THROUGH 2021 (\$ MILLIONS)	140
TABLE 85 NUMBER OF ORGAN DONATIONS IN MALAYSIA BY TYPE OF DONOR, 2013	141
TABLE 86 NUMBER OF ORGAN TRANSPLANTS IN MALAYSIA BY TYPE OF ORGAN, 2013	141
TABLE 87 NUMBER OF ORGAN DONATIONS IN NEW ZEALAND BY TYPE OF DONOR, 2015	142
TABLE 88 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN NEW ZEALAND BY TYPE OF ORGAN, 2015	142
TABLE 89 TRANSPLANT DIAGNOSTICS COMPANY PRESENT IN ASIA	142
TABLE 90 ROW TRANSPLANT DIAGNOSTICS MARKET BY COUNTRY, THROUGH 2021 (\$ MILLIONS)	143
TABLE 91 ROW TRANSPLANT DIAGNOSTICS MARKET BY END USER, THROUGH 2021 (\$ MILLIONS)	143

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 92 COMMUNICABLE AND NONCOMMUNICABLE DISEASES LEADING TO MORTALITY IN BRAZIL, 2014 (%)	144
TABLE 93 NUMBER OF ORGAN DONATIONS IN BRAZIL BY TYPE OF DONOR, 2015	144
TABLE 94 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN BRAZIL BY TYPE OF ORGAN, 2015	144
TABLE 95 AGE ADJUSTED HOSPITALIZATION RATE DUE TO CHRONIC DISEASES IN ISRAEL, 2013 (PER 100,000 ABOVE 15 YEARS)	145
TABLE 96 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN ISRAEL BY TYPE OF ORGAN, 2015	146
TABLE 97 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN ISRAEL BY TYPE OF ORGAN, 2015	146
TABLE 98 NUMBER OF ORGAN DONATIONS IN IRAN BY TYPE OF DONOR, 2015	146
TABLE 99 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN IRAN BY TYPE OF ORGAN, 2015	147
TABLE 100 NUMBER OF TISSUE TRANSPLANT PROCEDURES IN IRAN BY TYPE OF TISSUE, 2015	147
TABLE 101 NUMBER OF ORGAN DONATIONS IN SAUDI ARABIA BY TYPE OF DONOR, 2015	148
TABLE 102 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN SAUDI ARABIA BY TYPE OF ORGAN, 2015	148
TABLE 103 PATENTS REGISTERED/APPROVED BY COUNTRY, 2010-2016 (NO./%)	150
TABLE 104 PATENTS REGISTERED/APPROVED IN U.S. BY TYPE OF PRODUCT, 2010-2016 (NO./%)	151
TABLE 105 PATENTS REGISTERED/APPROVED IN CHINA BY TYPE OF PRODUCT, 2010-2016 (NO./%)	153
TABLE 106 PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016 (NO./%)	154
TABLE 107 PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016	154
TABLE 108 PATENTS REGISTERED/APPROVED BY TYPE OF PRODUCT, 2010-2016 (NO./%)	155
TABLE 109 PATENTS RELATED TO TRANSPLANTS	157
TABLE 110 RECENT DEVELOPMENTS OF ABBOTT LABORATORIES	167
TABLE 111 ABBOTT LABORATORIES FINANCIALS, 2013-2015 (\$ MILLIONS/%)	168
TABLE 112 RECENT DEVELOPMENTS OF AFFYMETRIX INC.	169
TABLE 113 AFFYMETRIX INC. FINANCIALS, 2012-2014 (\$ MILLIONS/%)	169
TABLE 114 ASTELLAS PHARMA INC. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	170
TABLE 115 RECENT DEVELOPMENTS OF BIOFORTUNA LTD.	171
TABLE 116 BIOFORTUNA LTD. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	172
TABLE 117 RECENT DEVELOPMENTS OF BIO-RAD LABORATORIES	173
TABLE 118 BIO-RAD LABORATORIES FINANCIALS, 2013-2015 (\$ MILLIONS/%)	173
TABLE 119 RECENT DEVELOPMENTS OF CAREDX INC.	174
TABLE 120 CAREDX INC. FINANCIALS, 2012-2014 (\$ MILLIONS/%)	175
TABLE 121 RECENT DEVELOPMENTS OF DIASORIN S.P.A.	176
TABLE 122 DIASORIN S.P.A. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	176
TABLE 123 RECENT DEVELOPMENTS OF F. HOFFMANN-LA ROCHE AG	177
TABLE 124 F. HOFFMANN-LA ROCHE AG FINANCIALS, 2013-2015 (\$ MILLIONS/%)	178
TABLE 125 RECENT DEVELOPMENTS OF GENDX	180
TABLE 126 RECENT DEVELOPMENTS OF ILLUMINA INC.	181
TABLE 127 ILLUMINA INC. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	182
TABLE 128 RECENT DEVELOPMENTS OF IMMUCOR INC.	183



<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 129 IMMUCOR INC. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	183
TABLE 130 RECENT DEVELOPMENTS OF LINKAGE BIOSCIENCES	184
TABLE 131 RECENT DEVELOPMENTS OF LUMINEX CORP.	185
TABLE 132 LUMINEX CORP. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	186
TABLE 133 RECENT DEVELOPMENTS OF OLERUP SSP AB	187
TABLE 134 RECENT DEVELOPMENTS OF QIAGEN N.V.	188
TABLE 135 QIAGEN N.V. FINANCIALS, 2013-2015 (\$ MILLIONS/%)	189
TABLE 136 SIGMA-ALDRICH FINANCIALS, 2013-2015 (\$ MILLIONS/%)	190
TABLE 137 RECENT DEVELOPMENTS OF THERMO FISHER SCIENTIFIC INC.	191
TABLE 138 THERMO FISHER SCIENTIFIC FINANCIALS, 2013-2015 (\$ MILLIONS/%)	192
TABLE 139 RECENT DEVELOPMENTS OF TRANSPLANT GENOMICS INC.	193
TABLE 140 LIST OF PATENTS ISSUED IN CANADA	195
TABLE 141 LIST OF PATENTS ISSUED IN CHINA	195
TABLE 142 LIST OF PATENTS IN ISSUED EUROPE (WO)	196
TABLE 143 LIST OF PATENTS ISSUED IN EUROPE	197
TABLE 144 LIST OF PATENTS ISSUED BY THE EUROPEAN PATENT OFFICE (EPO)	197
TABLE 145 LIST OF PATENTS ISSUED IN JAPAN	197
TABLE 146 LIST OF PATENTS ISSUED IN KOREA	198
TABLE 147 LIST OF PATENTS ISSUED IN THE RUSSIAN FEDERATION	198
TABLE 148 LIST OF PATENTS ISSUED IN SINGAPORE	198

**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE GLOBAL MARKET FOR TRANSPLANT DIAGNOSTICS BY REGION, 2015-2021 (\$ MILLIONS)	8
FIGURE 1 NUMBER OF KIDNEY TRANSPLANTS IN NORTH AMERICA BY COUNTRY, 2015	22
FIGURE 2 NUMBER OF LIVER TRANSPLANTS IN NORTH AMERICA BY COUNTRY, 2015	22
FIGURE 3 NUMBER OF ORGAN DONATIONS IN NORTH AMERICA BY TYPE OF DONOR, 2015	23
FIGURE 4 NUMBER OF TRANSPLANTS BY TYPE OF ORGAN IN U.S., JANUARY 1988-JUNE 2016	24
FIGURE 5 TRANSPLANT PROCEDURES PERFORMED BY ORGAN TYPE IN U.S., JANUARY 1988-JUNE 2016 (%)	25
FIGURE 6 NUMBER OF TRANSPLANTS BY AGE OF RECIPIENT IN U.S., JANUARY 1988-JUNE 2016	26
FIGURE 7 NUMBER OF TRANSPLANTS BY TYPE OF DONOR IN U.S., 2011-2015	26
FIGURE 8 NUMBER OF ORGAN DONATIONS IN U.S. BY TYPE OF DONOR, 2015	28
FIGURE 9 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN U.S. BY TYPE OF ORGAN, 2015	28
FIGURE 10 NUMBER OF ORGAN DONATIONS IN CANADA BY TYPE OF DONOR, 2015	29
FIGURE 11 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN CANADA BY TYPE OF ORGAN, 2015	31
FIGURE 12 NUMBER OF ORGAN DONATIONS IN MEXICO BY TYPE OF DONOR, 2015	32
FIGURE 13 NUMBER OF ORGAN TRANSPLANT PROCEDURES IN MEXICO BY TYPE OF ORGAN, 2015	32
FIGURE 14 NUMBER OF KIDNEY TRANSPLANTS IN EUROPE BY COUNTRY, 2015	34
FIGURE 15 NUMBER OF LIVER TRANSPLANTS IN EUROPE BY COUNTRY, 2015	34
FIGURE 16 NUMBER OF ORGAN DONATIONS IN EUROPE BY TYPE OF DONOR, 2015	35
FIGURE 17 HYPERTENSIVE DISEASES IN EUROPE BY COUNTRY, 2015 (%)	35
FIGURE 18 NUMBER OF DEATHS CAUSED BY CIRCULATORY SYSTEM DISEASES IN EUROPE BY COUNTRY, 2012 (%)	36
FIGURE 19 NUMBER OF ORGAN DONATIONS BY TYPE OF DONOR IN EUROPE (FRANCE, GERMANY AND UNITED KINGDOM), JANUARY 1988-JUNE 2016	37
FIGURE 20 NUMBER OF TRANSPLANT PROCEDURES BY TYPE OF ORGAN IN EUROPE (FRANCE, GERMANY AND UNITED KINGDOM), JANUARY 1988-JUNE 2016	38
FIGURE 21 NUMBER OF KIDNEY TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY, 2015	40
FIGURE 22 NUMBER OF LIVER TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY, 2015	40
FIGURE 23 NUMBER OF LIVER TRANSPLANTS IN ASIA-PACIFIC BY COUNTRY AND TYPE OF DONOR, 2015	41
FIGURE 24 NUMBER OF ORGAN/TISSUE TRANSPLANT PROCEDURES BY TYPE OF DONOR IN HONG KONG, 2015	42
FIGURE 25 NUMBER OF ORGAN TRANSPLANTS FROM DECEASED DONORS BY TYPE OF ORGAN IN JAPAN, 2015	43
FIGURE 26 NUMBER OF ORGAN DONATIONS BY TYPE OF DONOR IN AUSTRALIA, 2015	44
FIGURE 27 NUMBER OF ORGAN TRANSPLANTS BY TYPE OF ORGAN IN AUSTRALIA, 2015	45
FIGURE 28 NUMBER OF TISSUE TRANSPLANT PROCEDURES BY TYPE OF TISSUE IN AUSTRALIA, 2015	46
FIGURE 29 HISTORY OF THE HOPE ACT, 2013	59
FIGURE 30 MAJOR STRATEGIES ADOPTED BY PLAYERS IN THE TRANSPLANT DIAGNOSTICS MARKET	63

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
FIGURE 31 GLOBAL POPULATION AGED 60 AND OVER BY REGION, 2015 (NO.)	74
FIGURE 32 WAITING LIST FOR ORGANS IN U.S. BY TYPE OF ORGAN AS OF JULY 15, 2016 (NO.)	80
FIGURE 33 WAITING LIST FOR ORGANS IN U.S. BY AGE OF DONOR AS OF JULY 15, 2016 (NO.)	80
FIGURE 34 WORKFLOW FOR POLYMERASE CHAIN REACTION	87
FIGURE 35 PATENTS REGISTERED/APPROVED BY COUNTRY, 2010-2016 (%)	150
FIGURE 36 PATENTS REGISTERED/APPROVED IN U.S. BY TYPE OF PRODUCT, 2010-2016 (%)	152
FIGURE 37 PATENTS REGISTERED/APPROVED IN CHINA BY TYPE OF PRODUCT, 2010-2016 (%)	153
FIGURE 38 PATENTS REGISTERED/APPROVED BY MARKET PARTICIPANTS, 2010-2016 (%)	155
FIGURE 39 PATENTS REGISTERED/APPROVED BY TYPE OF PRODUCT, 2010-2016 (%)	156